Travere Therapeutics Inc Topline Interim Results from the Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy Corporate Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst : I'll also add my congratulations here. Maybe if you can clarify what data were available for you to look at in terms of, you went over that it's all of the data at week 36, but is there anything you can offer us in terms of maybe the average follow-up that these patients had or the number of patients that are out to 1 year and 2 years? If the enrollment curves were linear, I think it's like 90 or 100 patients, but you had 2 years of data for, if you can maybe confirm that range? And then just because I've been getting this question, can you confirm that the eGFR data that you're looking at is completely unblinded? And then the language in the PR stressed that the eGFR data could be indicative of a potentially clinically meaningful treatment effect after 2 years for eGFR. Is that synonymous with statistically significant, I guess? Or is clinically meaningful also would be considered statistically significant in terms of what you guys are powered to, I guess, to test in terms of the difference in eGFR at year 2?

Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst : Maybe if you can just remind us the powering for PROTECT in terms of why eGFR is -- or what difference in the eGFR slope that PROTECT is powered for at 2 years?

Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst : Okay. And just one more small one, if I can? Just because I've been getting this. Can you just confirm that all the data that you've been able to see from this week 36 analysis is unblinded?

Question: Michelle Lim Gilson - Canaccord Genuity Corp., Research Division - Analyst : Okay. And congratulations again on this data. They look great.